Cariprazine hydrochloride
Approved medicineAlso known as Vraylar, cariprazine (as hydrochloride), cariprazine HCl.
Recent clinical, regulatory, research and industry developments relating to this drug.
<![CDATA[What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice]]>
Marketing authorisation: Reagila (EMA)
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Indication: Reagila is indicated for the treatment of schizophrenia in adult patients.
Evidence ↗Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.
- RxNorm (U.S. National Library of Medicine) — drug identity
- Regulatory event sources are credited in the Regulatory Timeline above.